Med Ed Report briefs: February 2013

Lisa Keilty
Lisa Keilty

The economic crisis in Spain is affecting pharma funding for CME, says WentzMiller Global Services. It remains to be seen how declining government reimbursement rates in the EU will affect pharma spending for professional education, the consulting firm noted in its Dec. 2012-Jan. 2013 newsletter.

Meeting support firm Plannernet started a compliance division, PMC2. It will be led by new hire Lisa Keilty, CMP, who during her 10 years at Pfizer built its international meeting organization. She then started her own firm. In her new role, Keilty will seek to apply her knowledge of regulations to safeguard client compliance.

Physician social network QuantiaMD promoted Mike Coyne from president to CEO, and appointed Daniel Malloy as SVP, the firm said. Eric Schultz, QuantiaMD's founder and current CEO, moves to executive chairman.

Meeting Professionals International (MPI) said it was awarded a two-year agreement to co-develop sessions at the World Congress Global Medical Meetings Summit, taking place on February 28- March 1, in Philadelphia. MPI is also moderating a panel set to include meetings professionals from Daiichi Sankyo and Novartis.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.